论文部分内容阅读
目的研究甘露聚糖肽对口腔黏膜病患者的临床疗效及淋巴细胞活性的影响。方法本次筛选2015年6月至2016年6月在我院治疗的98例口腔黏膜病患者作为研究对象,随机分为常规组和治疗组,两组患者各49例。常规组患者接受常规治疗,治疗组患者在常规组治疗的基础上,加甘露聚糖肽治疗,对比两组患者临床疗效以及淋巴细胞活性变化。结果进行治疗后,治疗组治疗总有效率为95.92%,常规组治疗总有效率为81.63%,治疗组临床治疗疗效显著高于常规组。常规组患者的T淋巴细胞CD3、CD4明显低于治疗组患者,治疗组患者的CD8明显低于常规组,差异具有统计学意义(P<0.05)。结论甘露聚糖肽用于口腔黏膜病患者的治疗,临床效果显著,有效的提升了临床疗效,有效的改善患者病情,减少不良反应发生率,在临床治疗上值得使用和推广。
Objective To study the effect of mannan peptide on the clinical efficacy and lymphocyte activity in patients with oral mucosal disease. Methods A total of 98 patients with oral mucosal diseases treated in our hospital from June 2015 to June 2016 were randomly divided into routine and treatment groups, 49 cases in each group. The patients in the conventional group received routine treatment. The patients in the treatment group were treated with mannan peptide on the basis of conventional treatment, and the clinical efficacy and the change of lymphocyte activity were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 95.92%, the total effective rate of the conventional group was 81.63%. The clinical efficacy of the treatment group was significantly higher than that of the conventional group. The CD3 and CD4 in T lymphocytes of patients in the conventional group were significantly lower than those in the treatment group. The CD8 of the patients in the treatment group was significantly lower than that in the conventional group (P <0.05). Conclusion Mannatide for the treatment of oral mucosal disease patients, the clinical effect was significant, effectively enhance the clinical efficacy, effectively improve the patient’s condition, reduce the incidence of adverse reactions, the clinical treatment worth the use and promotion.